Abstract
Knee osteoarthritis (KOA) is a common chronic disease of high patient and societal impact. The etiology is multifactorial; pain sources include both intra- and extra-articular tissues. A number of alternative therapies have been assessed for KOA. Patients are often refractory to best-practice conservative management, and the development of new therapy has been called for by national health services groups. Prolotherapy is an outpatient therapy for chronic musculoskeletal pain including KOA. Protocols include injection at attachments of soft-tissue supportive structures such as ligaments and tendons, and within intra-articular spaces. Although the understanding of mechanism is not well understood, a small but growing body of literature suggests that prolotherapy may be appropriate therapy for carefully selected patients refractory to conventional treatment. This article summarizes evidence from basic and clinical science for use of prolotherapy among patients with KOA.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Felson DT. Epidemiology of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. Oxford: Oxford University Press; 2003. p. 9–16.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.
Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. Treatment of primary and secondary osteoarthritis of the knee. Agency for Healthcare Research and Quality (Publication No. 07-E012): Evidence Report/Technology Assessment: Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-Based Practice Center under Contract No. 290-02-0026). Rockville, MD. 2007;157.
Altman RD. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43:1905–15.
Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2001;1:CD002947.
Morelli V, Naquin C, Weaver V. Alternative therapies for traditional disease states: osteoarthritis. Am Fam Physician. 2003;15:339–44.
Richmond J, Hunter D, Irrgang J, et al. Treatment of osteoarthritis of the knee (nonarthroplasty). J Am Acad Orthop Surg. 2009;17(9):591–600.
Rath L. Knee replacement and revision surgeries on the rise. 2015; http://www.arthritis.org/living-with-arthritis/treatments/joint-surgery/types/knee/knee-replacement-younger-patients.php. Accessed 17 Nov 2015.
Skou ST, Roos EM, Laursen MB, et al. A randomized, controlled trial of total knee replacement. N Engl J Med. 2015;373(17):1597–606.
National Research Council. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press; 2009.
Schultz L. A treatment for subluxation of the temporomandibular joint. JAMA. 1937;109(13):1032–5.
• Hackett GS, Hemwall GA, Montgomery GA. Ligament and tendon relaxation treated by prolotherapy. 5th ed. Oak Park: Gustav A. Hemwall; 1993. Originally published in the 1950s, this text establishes the intellectual foundation of prolotherapy. The injection protocols used in the studies reviewed in this paper have their origin in this book.
DeChellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: prolotherapy, platelet-rich plasma, and stem cell therapy-theory and evidence. Tech Reg Anesth Pain Manag. 2011;15:74–80.
Rabago D, Slattengren A, Zgierska A. Prolotherapy in primary care. Prim Care. 2010;37:65–80.
Banks A. A rationale for prolotherapy. J Orthop Med. 1991;13:54–9.
Jensen K, Rabago D, Best TM, Patterson JJ, Vanderby R. Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res. 2008;26:816–23.
• Jensen KT, Rabago D, Best TM, Patterson JJ, Vanderby R. Longer term response of knee ligaments to prolotherapy in a rat injury model. Am J Sports Med. 2008;36:1347–57. This basic science paper evaluated dextrose in a stretch injury rat model. It reported biological changes compared to control injection, including increased surface area of medial collateral ligaments in response to prolotherapy.
Yoshi T, Zhao C, Schmelzer JD, Low PA, An K, Amadio A. The effects of hypertonic dextrose injection on connective tissue and nerve conduction through the rabbit carpal tunnel. Arch Phys Med Rehabil. 2009;90:333–9.
• Rabago D, Kijowski R, Woods M, et al. Association between disease-specific quality-of-life and magnetic resonance imaging outcomes in a clinical trial of prolotherapy for knee osteoarthritis. Arch Phys Med Rehabil. 2013;94(11):2075–82. This study reported that prolotherapy, as a treatment for knee osteoarthritis, does not slow or reverse cartilage volume loss in knee osteoarthritis as assessed by MRI. However, researchers found that among prolotherapy recipients, but not control therapy recipients, cartilage volume stability on MRI predicted pain score change, suggesting that the mechanism of action of prolotherapy may include pain-specific neural effects.
Lyftogt J. Pain conundrums: which hypothesis? Central nervous system sensitization versus peripheral nervous system autonomy. Australas Musculoskelet Med. 2008;13:72–4.
Donaldson LF. Neurogenic mechanisms in arthritis. In: Jancso G, editor. Neurogenic inflammation in health and disease, vol. 8. Amsterdam: Elsevier; 2009. p. 211–41.
Nagy I, Paule CC, White JPM. Molecular mechanisms of TRPV1-mediated pain. Neuroimmune Biol. 2009;8:75–99.
• Rabago D, Best TM, Beamsley M, Patterson J. A systematic review of prolotherapy for chronic musculoskeletal pain. Clin J Sport Med. 2005;15(5):376–80. This systematic review assessed the total prolotherapy literature through 2005. Reports were largely limited to successful cases and retrospective and prospective case series, but a series of higher quality randomized controlled trials reported mixed outcomes for low back pain.
Yelland MJ, Del Mar C, Pirozo S, Schoene ML. Prolotherapy injections for chronic low back pain: a systematic review. Spine. 2004;29:2126–33.
Shuman D. Sclerotherapy: statisitics on its effectiveness of unstable joint conditions. Osteopat Prof. 1954;11–15:37–8.
Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med. Mar 2000;6(2):68–74, 77–80.
• Rabago D, Zgierska A, Fortney L, et al. Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: an uncontrolled study with one-year follow-up. J Altern Complement Med. 2012;18:408–14. This open-label study using validated self-reported outcome measures was the first to suggest that a “whole joint” prolotherapy injection protocol using both intra- and extra-articular dextrose injections has a potential benefit for knee osteoarthritis.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.
Ehrich E, Davies G, Watson D, Bolognese J, Seidenberg B, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27(11):2635–41.
Tubach F, Wells G, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol. 2005;32(10):2025–9.
Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991;27:10–2.
•• Dumais R, Benoit C, Dumais A, et al. Effect of regenerative injection therapy on fuction and pain in patients with knee osteoarthitis: a randomized crossover study. Pain Med. 2012;13:990–9. This randomized study reported that prolotherapy is an effective treatment for symptomatic knee osteoarthritis compared to unblinded control.
•• Rabago D, Patterson JJ, Mundt M, et al. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med. 2013;11(3):229–37. This benchmark randomized controlled trial reported that prolotherapy for knee osteoarthritis is statistically superior to blinded control injection therapy and non-blinded, at-home exercise by margins that meet criteria for clinical importance. It suggests that prolotherapy, for this condition, is both efficacious and effective.
Grote W, DeLucia R, Waxman R, Zgierska A, Wilson JJ, Rabago D. Repair of a complete anterior cruciate tear using prolotherapy: a case report. Int Musculoskelet Med. 2009;31(4):159–65.
Scarpone M, Rabago D, Zgierska A, Arbogest J, Snell ED. The efficacy of prolotherapy for lateral epicondylosis: a pilot study. Clin J Sport Med. 2008;18:248–54.
Rabago D, Patterson JJ, Mundt M, et al. Dextrose and morrhuate sodium injections (prolotherapy) for knee osteoarthritis: the results of a prospective open label trial. J Altern Complement Med. 2014;20(5):383–91.
Hunter DJ, Niu J, Zhang Y, et al. Change in cartilage morphometry: a sample of the progression cohort of the osteoarthritis initiative. Ann Rheum Dis. 2009;68:349–56.
• Rabago D, Mundt M, Zgierska A, Grettie J. Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: long term outcomes. Complement Ther Med. 2015;23(3):388–95. The long-term effects of prolotherapy for participants with knee osteoarthritis were assessed in this study. Researchers found prolotherapy recipients continued to improve through an average of 2.5 ± 0.6 years. However, the cohort was divided between “responders” and “non-responders.” The majority of participants (82 %) reported continued improved outcomes at the long-term follow-up, but a minority of participants (18 %) worsened compared to baseline status.
Acknowledgments
We acknowledge the significant contributions to prolotherapy of Jeffrey J Patterson, DO. He was the primary injector in the studies by Rabago et al., and the inspiration for this work. Jeff was a compassionate physician, generous mentor and dear friend who dedicated his life to improving the human condition.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Musculoskeletal Rehabilitation.
Rights and permissions
About this article
Cite this article
Nourani, B., Rabago, D. Prolotherapy for Knee Osteoarthritis: A Descriptive Review. Curr Phys Med Rehabil Rep 4, 42–49 (2016). https://doi.org/10.1007/s40141-016-0111-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40141-016-0111-z